Beijing Enze Kangtai Biotechnology

Beijing Enze Kangtai Biotechnology, also known as ECHO Biotech, is a high-tech company established in 2017, focusing on the development and clinical transformation of exosome technology. The company was co-founded by CEO Kong Guanyi and CTO Dr. Zhao Libo. Dr. Zhao began his full-time entrepreneurial journey in 2016 after leaving the Institute of Chemistry at the Chinese Academy of Sciences, driven by the conviction that the exosome field held significant potential for creating high-value enterprises. Initially located in the Peking University Medical Industrial Park, the company secured its Angel round of financing from Lanfeng Capital and Enran Venture Capital just two months after its establishment.

The company's operations are divided into two main segments. The first involves providing CRO and CDMO services for exosome innovative drug research and development, which includes carrier design and development of engineered exosome drugs. The second segment focuses on translational medicine research services centered around basic exosome research, carried out in collaboration with clinical experts. The business model generates revenue through these contract research and manufacturing services, as well as by providing exosome-related products and comprehensive research solutions to scientific institutions. Its client base includes over 100 major hospitals and scientific research units in China, along with various biopharmaceutical and precision medicine companies.

ECHO Biotech has developed three core platforms: Exoomics®, a multi-omics platform for hospitals and research institutions; Echosome®, an engineered exosome platform offering CRO services for drug development to biopharmaceutical companies; and EchoPharm®, which provides CDMO services and raw material production. The company's R&D pipeline targets areas such as tumor immunity, rare diseases, and neurological disorders. For instance, in rare disease treatment, it employs exosome-based protein replacement therapy. A significant milestone was achieved when its subsidiary, Beijing Enkang Pharmaceutical Co., Ltd., received both a US FDA Drug Master File (DMF) and an International Nomenclature of Cosmetic Ingredients (INCI) registration for its human mesenchymal stem cell exosome raw material, GoldenExo®. The company has successfully raised multiple rounds of funding, including an A+ round led by Baidu Ventures and an A++ round in March 2023, to advance its technology platforms and accelerate clinical applications.

Keywords: exosome technology, clinical transformation, CRO services, CDMO services, translational medicine, engineered exosomes, drug delivery, tumor immunity, rare diseases, neurological disorders, molecular biology, bioinformatics, cell biology, exosome research, drug discovery, life sciences, gene therapy, biologics, biopharmaceutical, contract research organization, contract development and manufacturing organization, exosome manufacturing, GMP, preclinical development